NCT05728996 (NOVA) is a clinical trial in Acute HIV Infection, sponsored by Prof. Jan Prins.

Who is sponsoring NCT05728996?

NCT05728996 is sponsored by Prof. Jan Prins.

What condition does NCT05728996 study?

NCT05728996 studies Acute HIV Infection.

Is NCT05728996 still recruiting?

NCT05728996 is currently recruiting now. Last updated 15 February 2023.

Last reviewed 2023-02-15 · How we verify

NCT05728996: NOVA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Netherlands Cohort Study on Acute HIV Infection

Recruiting now Last updated 15 February 2023

What this trial tests

trial in Acute HIV Infection in 183 participants. Currently enrolling.

Timeline

1 August 2015

Primary endpoint
1 August 2028

1 August 2028

Quick facts

Lead sponsor	Prof. Jan Prins
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	183
Start date	1 August 2015
Primary completion	1 August 2028
Estimated completion	1 August 2028
Sites	1 location across Netherlands

Conditions studied

Acute HIV Infection — all drugs for Acute HIV Infection →

Sponsor

Prof. Jan Prins

Who can join

18 and older, any sex, with Acute HIV Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Investigation of the size, variability and localization of the (pro) viral reservoir and the properties of HIV-specific immune response related to "post-treatment viral remission' achievement and / or duration. In addition we will study the factors that determine latency in the different host cells, their sensitivity to induction of replication competent virus by various agents and the potential application of these agents in "post-treatment viral remission". This all will be studied in patients included during acute phase of the infection who start antiretroviral therapy immediately upon diagnosis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Perceptions of Rapid Antiretroviral Therapy Initiation Among Participants of The Netherlands Cohort Study on Acute HIV Infection.
van Paassen P, Dijkstra M, Peay HL, Rokx C, et al · · 2024 · cited 3× · PMID 37791419 · DOI 10.1089/aid.2022.0169

Verify or expand the search:

Other recruiting trials for Acute HIV Infection

Currently open trials in the same condition.

NCT06484335 — RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV · Phase 1 · recruiting
NCT05719441 — A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation Dur · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05728996 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Prof. Jan Prins
Last refreshed: 15 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05728996.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing